Online inquiry

IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13319MR)

This product GTTS-WQ13319MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TFPI gene. The antibody can be applied in Hemophilia research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001032281.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7035
UniProt ID P10646
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13319MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5705MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ12771MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ14150MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ3953MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ2929MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ10289MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ1026MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ6738MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS 992
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW